Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: Safety and efficacy

Annals of Oncology

Volumn 17, Issue 12, 2006, Pages 1766-1771

  Baz, R ^a   Walker, E ^b   Karam, M A ^a   Choueiri, T K ^a   Jawde, R A ^a   Bruening, K ^b   Reed, J ^a   Faiman, B ^a   Ellis, Y ^a   Brand, C ^a   Srkalovic, G ^c   Andresen, S ^b   Knight, R ^c   Zeldis, J ^c   Hussein, M A ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c CELGENE CORPORATION   (United States)

Author keywords

Doxil; Lenalidomide; Multiple Myeloma; Reduced dose dexamethasone; Refractory

Indexed keywords

ACETYLSALICYLIC ACID; ACICLOVIR; AMOXICILLIN; BORTEZOMIB; DEXAMETHASONE; DOXORUBICIN; HISTAMINE H2 RECEPTOR ANTAGONIST; LENALIDOMIDE; PREDNISONE; THALIDOMIDE; VINCRISTINE;

ACUTE KIDNEY FAILURE; ADULT; ALLERGIC REACTION; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CANDIDIASIS; CELLULITIS; CLINICAL TRIAL; CONFUSION; CONSTIPATION; DEEP VEIN THROMBOSIS; DIARRHEA; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERANCE; DRUG WITHDRAWAL; DYSPEPSIA; DYSPNEA; EDEMA; ELECTROLYTE DISTURBANCE; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; FLUID RETENTION; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HAND FOOT SYNDROME; HEADACHE; HEART ARRHYTHMIA; HUMAN; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPOTHYROIDISM; LEUKOPENIA; LOW DRUG DOSE; LUNG EMBOLISM; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MENTAL DISEASE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MUSCLE CRAMP; MUSCLE WEAKNESS; MYALGIA; NAUSEA; NEUROPATHY; NEUTROPENIA; PANCYTOPENIA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; RASH; SIDE EFFECT; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT OUTCOME; TREMOR; TUMOR CELL DESTRUCTION; UNSPECIFIED SIDE EFFECT; VOMITING;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOXORUBICIN; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MULTIPLE MYELOMA; POLYETHYLENE GLYCOLS; RECURRENCE; THALIDOMIDE;

EID: 33845350847     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl313     Document Type: Article

References (26)

1. Gertz MA, Kalish LA, Kyle RA et al. Phase III study comparing vincristine, doxorubicin (Adriamycin), and dexamethasone (VAD) chemotherapy with VAD plus recombinant interferon alfa-2 in refractory or relapsed multiple myeloma. An Eastern Cooperative Oncology Group study. Am J Clin Oncol 1995; 18: 475-480.
2. Blade J, Esteve J. Treatment approaches for relapsing and refractory multiple myeloma. Acta Oncol 2000; 39: 843-847.
3. Richardson PG, Barlogie B, Berenson J et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348: 2609-2617.
4. Singhal S, Mehta J, Desikan R et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341; 1565-1571.
5. Rajkumar SV. Novel approaches to the management of myeloma. Oncology (Williston Park) 2005; 19: 621-625.
6. Hussein MA, Saleh M, Ravandi F et al. Phase 2 study of arsenic trioxide in patients with relapsed or refractory multiple myeloma. Br J Haematol 2004; 125: 470-476.
7. Hussein MA. New treatment strategies for multiple myeloma. Semin Hematol 2004; 41: 2-8.
8. Hussein MA, Baz R, Srkalovic G et al. Phase 2 study of pegylated liposomal doxorubicin, vincristine, reduced-schedule dexamethasone, and thalidomide in newly diagnosed and relapsed-refractory multiple myel. Mayo Clin Proc 2006; 81: 889-895.
9. Muller GW, Corral LG, Shire MG et al. Structural modifications of thalidomide produce analogs with enhanced tumor necrosis factor inhibitory activity. J Med Chem 1996; 39: 3238-3240.
10. Muller GW, Chen R, Huang SY et al. Amino-substituted thalidomide analogs: Potent inhibitors of TNF-alpha production. Bioorg Med Chem Lett 1999; 9: 1625-1630.
11. Marriott JB, Westby M, Cookson S et al. CC-3052: A water-soluble analog of thalidomide and potent inhibitor of activation-induced TNF-alpha production. J Immunol 1998; 161: 4236-4243.
12. Marriott JB, Clarke IA, Dredge K et al. Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells. Clin Exp Immunol 2002; 130: 75-84.
13. Dredge K, Marriott JB, Macdonald CD et al. Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects, Br J Cancer 2002; 87: 1166-1172.
14. Dredge K, Horsfall R, Robinson SP et al. Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. Microvasc Res 2005; 69: 56-63.
15. Hussein MA. Lenalidomide: Patient management strategies. Semin Hematol 2005; 42: S22-S25.
16. Richardson PG, Schlossman RL, Weller E et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002; 100: 3063-3067.
17. Rajkumar SV, Hayman SR, Lacy MQ et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 2005; 106: 4050-4053.
18. Baz R, Li L, Kottke-Marchant K et al. The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. Mayo Clin Proc 2005; 80: 1568-1574.
19. Jacobson JL, Hussein MA, Barlogie B et al. A new staging system for multiple myeloma patients based on the Southwest Oncology Group (SWOG) experience. Br J Haematol 2003; 122: 441-450.
20. Durie BG, Jacobson J, Barlogie B, Crowley J. Magnitude of response with myeloma frontline therapy does not predict outcome: Importance of time to progression in southwest oncology group chemotherapy trials. J Clin Oncol 2004; 22: 1857-1863.
21. Attal M, Harousseau JL, Stoppa AM et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Mad 1996; 335: 91-97.
22. Sallah S, Husain A, Wan J et al. The risk of venous thromboembolic disease in patients with monoclonal gammopathy of undetermined significance. Ann Oncol 2004; 15: 1490-1494.
23. Srkalovic G, Cameron MG, Rybicki L et al. Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease. Cancer 2004; 101: 558-566.
24. Zonder JA, Barlogie B, Durie BG et al. Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: Benefit of aspirin prophylaxis. Blood 2006; 108: 403.
25. Dimopoulos M, Spencer A, Attal M et al. Study of lenalidomide plus dexamethasone versus dexamethasone alone in relapsed or refractory multiple myeloma (MM): Results of a phase III study (MM-010). Blood 2005; 106: 11 (Abstr 6).
26. Richardson PG, Sonneveld P, Schuster MW et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352: 2487-2498.